• Evrysdi (risdiplam)

  Evrysdi (risdiplam) Survey

  Posted by kevin-schaefer on August 13, 2020 at 3:40 pm

  On Friday, August 7th, the FDA announced the approval of Evrysdi (Risdiplam), the first oral treatment for all types of SMA. BioNews frequently launches surveys to gauge the thoughts of community members. Your perspective may help better inform and improve how the medical industry treats people with SMA. Should this survey yield valuable insights, the results will be shared with the SMA community. This survey will take 2-3 minutes to complete. Your insights are appreciated.

  Click here to take the survey

  kevin-schaefer replied 3 years, 8 months ago 1 Member · 0 Replies

  • evrysdi
  • Genentech
  • risdiplam
  • Roche
  • SMA treatment
  • survey
• 0 Replies

Log In to Reply